Egret Therapeutics
PrivateLast Round
Seed
Feb 15, 2022
Company Overview
Egret Therapeutics is a biotechnology company that develops pharmaceutical drugs designed to treat neurological diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Egret Therapeutics Comparables
Compare Egret Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aeromics | 81% | |
| Remedy Pharmaceuticals | 80% | |
| ZZ Biotech | 74% |
Egret Therapeutics Funding Rounds
Historical fundraising activity
Egret Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Turret Capital | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 24, 2024
Grew 300% QoQ from 1 to 4 employees.
Egret Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Egret Therapeutics's valuation, stock price, and market status.
Is Egret Therapeutics a public or private company?
Egret Therapeutics is a private company.
What is the current stock price of Egret Therapeutics?
Egret Therapeutics is a private company, so its shares have no public market price. Caplight tracks Egret Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Egret Therapeutics worth (valuation)?
Valuation information for Egret Therapeutics is not publicly available.
Can I buy Egret Therapeutics stock?
Egret Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Egret Therapeutics's last funding round?
Egret Therapeutics's most recent funding round was Seed on February 15, 2022.
Who are the main investors in Egret Therapeutics?
Key investors in Egret Therapeutics include Turret Capital.
Will Egret Therapeutics IPO soon?
No public IPO plans have been announced for Egret Therapeutics.
How can I track Egret Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Egret Therapeutics's shares on secondary markets.